Under Development JAK Inhibitors for Dermatologic Diseases

In the document from January 1, 2020, Janus kinase (JAK) inhibitors were highlighted as a new and promising class of drugs in dermatology, particularly for their role in treating inflammatory diseases. These inhibitors target the JAK-STAT pathway, which is crucial for both innate and adaptive immunity, as well as hematopoiesis. Initially developed for rheumatologic and hematologic diseases, JAK inhibitors were also found to be effective for certain dermatologic conditions, including atopic dermatitis, psoriasis, vitiligo, and alopecia areata. They can be administered orally or topically. However, at the time of the document, JAK inhibitors were still relatively new in the field of dermatology, and there were ongoing trials to determine their efficacy and safety. The document summarized the development of JAK inhibitors for dermatologic diseases, with an emphasis on the anticipation of data from these trials.